Management of Polycystic Ovary Syndrome (PCOS)

Introduction to PCOS Management

• The management of PCOS requires a multicomponent lifestyle intervention as first-line treatment, combined with targeted therapies for related conditions, while addressing the underlying hormonal imbalance, as recommended by the European Society of Human Reproduction and Embryology 1

Diagnosis and Classification

• The diagnosis of PCOS requires the presence of at least two of the following three Rotterdam criteria: hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound, as recommended by the European Society of Human Reproduction and Embryology 2
• Polycystic Ovarian Morphology (PCOM) can be diagnosed by transvaginal ultrasound showing ≥25 follicles (2-9mm) in at least one ovary, with higher frequency transducers (≥8 MHz) used for optimal follicle visualization, according to the European Society of Human Reproduction and Embryology 2
• In adolescents, diagnosis of PCOS requires hyperandrogenism and persistent oligomenorrhea, with ultrasound criteria being less reliable, according to the European Society of Human Reproduction and Embryology 2

Clinical Implications and Risks

• PCOS is a complex endocrine disorder associated with significant clinical implications, including infertility, endometrial risks, and increased risk of pregnancy complications, as noted by the European Society of Human Reproduction and Embryology, the American College of Obstetricians and Gynecologists, the Endocrine Society, and the American Society for Reproductive Medicine 3, 4, 5
• Women with PCOS have a 30% increased risk of cardiovascular disease, 44% increased risk of ischemic heart disease, 36% increased risk of stroke, and up to 25% prevalence of diabetes mellitus, with composite cardiovascular disease: OR 1.30 (1.09-1.56), ischemic heart disease: OR 1.44 (1.13-1.84), and stroke: OR 1.36 (1.09-1.70) 6
• PCOS patients have 2-3 times higher odds of metabolic complications compared to controls, with 50% of PCOS patients having metabolic syndrome 6
• Major adverse cardiac events incidence is 40 per 10,000 person-years in PCOS vs 19 per 10,000 person-years in controls, with an adjusted incident risk 1.5 times higher in PCOS patients 7
• Depression prevalence can reach up to 30% in conditions with similar hormonal imbalances, and generalized anxiety disorder incidence is approximately 6 per 100 person-years in conditions with similar hormonal imbalances 7

Lifestyle Intervention

• Multicomponent lifestyle intervention is the cornerstone of PCOS management, and should include behavioral strategies to support sustainable lifestyle changes, as recommended by the European Society of Human Reproduction and Embryology 1
• Weight management is important to reduce androgen levels, with a weight loss of only 5-10% able to restore ovulation and improve fertility in women with PCOS, as recommended by the American College of Obstetricians and Gynecologists 4, 1
• Regular physical activity, with a minimum of 150 minutes weekly, is recommended for the management of insulin resistance, as suggested by the World Health Organization, and the American Heart Association recommends at least 250 minutes of moderate-intensity physical activity per week, including strength training 2-3 times a week, to reduce sedentary behavior and improve overall health 1, 8
• A balanced diet with attention to portion control and reduction of sugar-sweetened beverages is recommended for the management of insulin resistance, as suggested by the World Health Organization 1

Pharmacological Treatment

• Metformin is a first-line medication for PCOS with metabolic characteristics, with a starting dose of 500 mg/day with meals, gradually increasing to 1000-1500 mg/day in divided doses, and benefits including improved insulin resistance, regularized menstrual cycles, and reduced long-term cardiometabolic risks, as recommended by the Endocrine Society with a strength of evidence of high 4
• Clomiphene citrate is the first-line medication for ovulation induction in women with PCOS, with a dosage starting on day 5 of the cycle, and it has an 80% ovulation rate and 50% conception rate, as recommended by the American Society for Reproductive Medicine 3, 5
• Spironolactone 100 mg daily can be used to improve hirsutism, with visible improvement typically taking 6 months, and combined oral contraceptives (COCs) are first-line therapy for menstrual regulation, reducing hyperandrogenism, and endometrial protection in PCOS patients, but increase venous thromboembolism risk three to fourfold (up to 4 per 10,000 woman-years) in the general population, as recommended by the American College of Obstetricians and Gynecologists 9, 10, 1
• Oral micronized progesterone (200-300 mg daily for 12-14 days monthly) provides essential protection against endometrial hyperplasia, improves menstrual cycle regularity, and has a better safety profile compared to synthetic progestins, as recommended by the American College of Obstetricians and Gynecologists 11, 12, 1
• The American College of Obstetricians and Gynecologists recommends the levonorgestrel-releasing intrauterine device (LNG-IUD) as a first-line non-oral contraceptive option for patients with PCOS due to its effectiveness in providing endometrial protection, regulating menstrual cycles, and minimal impact on metabolic parameters, with a strength of evidence of high 13

Monitoring and Follow-up

• Regular consultations every 6 months are recommended to monitor blood pressure, lipid profile, menstrual cycles, weight changes, and metabolic parameters in women with PCOS, as recommended by the American Heart Association with a strength of evidence of moderate 4
• The American Diabetes Association recommends that women with PCOS be screened for gestational diabetes and pre-eclampsia during pregnancy, with a strength of evidence of high 4
• Persistent abnormal uterine bleeding despite treatment, signs of significant virilization, rapid development of symptoms, and significant weight gain or worsening insulin resistance despite treatment are all red flags that require prompt evaluation and adjustment of treatment, as recommended by the American College of Obstetricians and Gynecologists 5